Evidence map›Paper›PMID 32671729›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

Research on CRISPR/system in major cancers and its potential in cancer treatments.

Z Liu, Z Liao, Y Chen, L Zhou, W Huangting, H Xiao

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Z Liu *Department of Clinical Pharmacy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, 610041, Sichuan, China.
Z Liao *Department of Gynecology and Obstetrics, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.
Y ChenDepartment of Clinical Pharmacy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, 610041, Sichuan, China.
L ZhouDepartment of Clinical Pharmacy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, 610041, Sichuan, China.
W HuangtingDepartment of Clinical Pharmacy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, 610041, Sichuan, China.
H XiaoDepartment of Clinical Pharmacy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, 610041, Sichuan, China. xht927@163.com.ORCID http://orcid.org/0000-0003-1027-6054

Funding

Chengdu City Science and Technology Project Grant no.11PPYB010SF-289Sichuan Cancer Hospital Grant no. YB2019001The Cadre Health Care Research Project of Sichuan Province Grant No. 2019-801the Health Department of Sichuan Province 120111the Health Department of Sichuan Province 17ZD038the Health Department of Sichuan Province Grant no. 100491the National Key Specialty Construction Project of Clinical Pharmacy Grant no.30305030698the Science & Technology Program of Sichuan Province 2014FZ0103the Science & Technology Program of Sichuan Province 2015JQO027the Science & Technology Program of Sichuan Province 2015ZR0160the Science & Technology Program of Sichuan Province Grant no. 2009SZ0226the Young Scholars Foundation of Sichuan Provincial People's Hospital 30305030859the Young Scholars Foundation of Sichuan Provincial People's Hospital Grant no. 30305030606Zambon Pharmaceutical Scientific Research Foundation of the Chengdu Pharmaceutical Association Grant No. 201905
6 · The paper itself

Abstract

Cancer is a serious public health problem in the world and the prevention and control of cancer has become one of the health strategies of governments around the world. According to the data of the International Agency for Research on Cancer (IARC), about 8 million people die of cancer every year in the world. With the continuous progress of medical technology, there are many methods to treat cancer at present. However, many treatment methods have achieved different therapeutic effects, some of them have obvious toxic and side effects. Therefore, it is necessary to study simpler and more effective new therapies for alleviating pain and prolonging lifetime of patients. In this view, we focus on the application progress of CRISPR system in some major cancers and its potential in cancer treatments.

Indexed as

CRISPR-Cas SystemsBacterial ProteinsClustered Regularly Interspaced Short Palindromic RepeatsColorectal NeoplasmsCRISPR-Associated Protein 9CRISPR-Associated ProteinsEndodeoxyribonucleasesFemaleGene EditingGene Knockout TechniquesGenetic TherapyHumansImmunotherapyLiver NeoplasmsLung NeoplasmsLymphomaBacterial ProteinsCas12a proteinCRISPR-Associated Protein 9CRISPR-Associated ProteinsEndodeoxyribonucleasesCancerCRISPRTherapy

Identifiers

PMID32671729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.